Friday, July 10, 2026

pharma · Hepatitis C Virus Infection · Chronic Hepatitis B

Gilead Sciences Ireland

Gilead Sciences is a pharma organization headquartered in Foster City, USA. Primary therapeutic focus areas include Hepatitis C Virus Infection, Chronic Hepatitis B, HIV-1-infection, HCV Infection, Crohn's Disease. NovaP

333 Lakeside Drive, Foster City, CA 94404, US HQ
1987 Founded
14,602 Employees
EMA registrant Type
Company details
Status
Public
HQ
333 Lakeside Drive, Foster City, CA 94404, US
Founded
1987
Employees
14,602
Programs
26
Drugs
17
Patents
0
Clinical program

TDF

Approved · small molecule · Chronic Hepatitis B

TDF for Chronic Hepatitis B is a Approved program (small_molecule) at Gilead Sciences Ireland UC with 1 ClinicalTrials.gov record(s).

← All Gilead Sciences Ireland UC projects Approved small molecule completed

Internal code GS-US-174-0149

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Gilead Sciences Ireland UC
Phase
Approved
Modality
small_molecule
Indication
Chronic Hepatitis B
Status
completed
Trials
1

Clinical trials